{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T14:06:08Z","timestamp":1784210768987,"version":"3.55.0"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2017,5,26]],"date-time":"2017-05-26T00:00:00Z","timestamp":1495756800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2017,5,26]],"date-time":"2017-05-26T00:00:00Z","timestamp":1495756800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Liver Transpl"],"published-print":{"date-parts":[[2017,6]]},"abstract":"<jats:p>Nonselective beta\u2010blockers (NSBBs) have played an important role in the prevention of portal hypertensive bleeding in patients with cirrhosis. However, recent studies have suggested that NSBBs may be harmful in some patients with end\u2010stage liver disease. The purpose of this article is to evaluate the association between use of NSBB and the incidence of acute kidney injury (AKI). We conducted a nested case\u2010control study in a cohort of liver transplant wait\u2010list registrants. Each patient with AKI was matched to a control by the Model for End\u2010Stage Liver Disease\u2013Na score, age, serum creatinine, and follow\u2010up duration. Out of a total of 2361 wait\u2010list registrants, 205 patients developed AKI after a median follow\u2010up duration of 18.2 months. When compared with matched controls, ascites (79.0% versus 51.7%) and non\u2010Caucasian race (16.6% versus 7.8%) were more common among the cases. The frequency of NSBB use was higher among the cases than controls, albeit insignificantly (45.9% versus 37.1%; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.08). In multivariate analyses, the impact of nonselective beta blockade on the development of AKI was dependent on the presence of ascites: nonselective beta blockade in patients with ascites significantly increased the risk of AKI (hazard ratio [HR], 3.31; 95% confidence interval [CI], 1.57\u20106.95), whereas in patients without ascites, NSBB use reduced it (HR, 0.19; 95% CI, 0.06\u20100.60). Potential benefits and harms of a NSBB in terms of AKI depend on the presence of ascites in liver transplant candidates. NSBB therapy in patients with cirrhosis may need to be individualized. <jats:italic toggle=\"yes\">Liver Transplantation 23 733\u2013740 2017 AASLD<\/jats:italic>.<\/jats:p>","DOI":"10.1002\/lt.24744","type":"journal-article","created":{"date-parts":[[2017,2,10]],"date-time":"2017-02-10T22:56:43Z","timestamp":1486767403000},"page":"733-740","source":"Crossref","is-referenced-by-count":52,"title":["Beneficial and harmful effects of nonselective beta blockade on acute kidney injury in liver transplant candidates"],"prefix":"10.1097","volume":"23","author":[{"given":"Sang Gyune","family":"Kim","sequence":"first","affiliation":[{"name":"Digestive Disease Center and Research Institute, Department of Internal Medicine,Soonchunhyang University Bucheon Hospital,Bucheon,South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph J.","family":"Larson","sequence":"additional","affiliation":[{"name":"Department of Biomedical Statistics and Informatics,Mayo Clinic,Rochester,MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Sung","family":"Lee","sequence":"additional","affiliation":[{"name":"Clinical Research Center,Asan Medical Center,Seoul,South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry M.","family":"Therneau","sequence":"additional","affiliation":[{"name":"Department of Biomedical Statistics and Informatics,Mayo Clinic,Rochester,MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Ray","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology,Stanford University School of Medicine,Stanford,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2017,5,26]]},"reference":[{"key":"lt24744-bib-0001-20240115","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1002\/hep.21907","article-title":"Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis","volume":"46","year":"2007","journal-title":"Hepatology"},{"key":"lt24744-bib-0002-20240115","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1056\/NEJM198112033052302","article-title":"Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a controlled study","volume":"305","year":"1981","journal-title":"N Engl J Med"},{"key":"lt24744-bib-0003-20240115","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0016-5085(90)91308-S","article-title":"Propranolol in the prevention of recurrent variceal hemorrhage in cirrhotic patients. A controlled trial","volume":"98","year":"1990","journal-title":"Gastroenterology"},{"key":"lt24744-bib-0004-20240115","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJM199105303242202","article-title":"Beta\u2010adrenergic\u2010antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials. Franco\u2010Italian Multicenter Study Group","volume":"324","year":"1991","journal-title":"N Engl J Med"},{"key":"lt24744-bib-0005-20240115","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1053\/gast.2002.35955","article-title":"A randomized, controlled trial of medical therapy versus endoscopic ligation for the prevention of variceal rebleeding in patients with cirrhosis","volume":"123","year":"2002","journal-title":"Gastroenterology"},{"key":"lt24744-bib-0006-20240115","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/hep.20584","article-title":"Variceal ligation plus nadolol compared with ligation for prophylaxis of variceal rebleeding: a multicenter trial","volume":"41","year":"2005","journal-title":"Hepatology"},{"key":"lt24744-bib-0007-20240115","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1053\/jhep.2003.50133","article-title":"Hemodynamic response to pharmacological treatment of portal hypertension and long\u2010term prognosis of cirrhosis","volume":"37","year":"2003","journal-title":"Hepatology"},{"key":"lt24744-bib-0008-20240115","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1056\/NEJMoa044456","article-title":"Beta\u2010blockers to prevent gastroesophageal varices in patients with cirrhosis","volume":"353","year":"2005","journal-title":"N Engl J Med"},{"key":"lt24744-bib-0009-20240115","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1053\/j.gastro.2006.09.013","article-title":"Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review","volume":"131","year":"2006","journal-title":"Gastroenterology"},{"key":"lt24744-bib-0010-20240115","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/hep.25686","article-title":"Long\u2010term follow\u2010up of hemodynamic responders to pharmacological therapy after variceal bleeding","volume":"56","year":"2012","journal-title":"Hepatology"},{"key":"lt24744-bib-0011-20240115","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/ki.2014.328","article-title":"The definition of acute kidney injury and its use in practice","volume":"87","year":"2015","journal-title":"Kidney Int"},{"key":"lt24744-bib-0012-20240115","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.cgh.2013.03.018","article-title":"Acute kidney injury in patients with cirrhosis: perils and promise","volume":"11","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"lt24744-bib-0013-20240115","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/hep.23775","article-title":"Deleterious effects of beta\u2010blockers on survival in patients with cirrhosis and refractory ascites","volume":"52","year":"2010","journal-title":"Hepatology"},{"key":"lt24744-bib-0014-20240115","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/apt.13172","article-title":"Review article: spontaneous bacterial peritonitis\u2010\u2010bacteriology, diagnosis, treatment, risk factors and prevention","volume":"41","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"lt24744-bib-0015-20240115","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.jhep.2013.09.016","article-title":"The changing role of beta\u2010blocker therapy in patients with cirrhosis","volume":"60","year":"2014","journal-title":"J Hepatol"},{"key":"lt24744-bib-0016-20240115","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1053\/j.gastro.2006.02.010","article-title":"Evidence\u2010based incorporation of serum sodium concentration into MELD","volume":"130","year":"2006","journal-title":"Gastroenterology"},{"key":"lt24744-bib-0017-20240115","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/hep.21025","article-title":"Deaths on the liver transplant waiting list: an analysis of competing risks","volume":"43","year":"2006","journal-title":"Hepatology"},{"key":"lt24744-bib-0018-20240115","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/gut.2010.236133","article-title":"Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis","volume":"60","year":"2011","journal-title":"Gut"},{"key":"lt24744-bib-0019-20240115","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1136\/gutjnl-2014-308874","article-title":"Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites","volume":"64","year":"2015","journal-title":"Gut"},{"key":"lt24744-bib-0020-20240115","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1111\/apt.13577","article-title":"Lack of clinical or haemodynamic rebound after abrupt interruption of beta\u2010blockers in patients with cirrhosis","volume":"43","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"lt24744-bib-0021-20240115","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1136\/gutjnl-2015-309262","article-title":"U.K. guidelines on the management of variceal haemorrhage in cirrhotic patients","volume":"64","year":"2015","journal-title":"Gut"},{"key":"lt24744-bib-0022-20240115","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/hep.21089","article-title":"Improved prognosis for patients hospitalized with esophageal varices in Sweden 1969\u20102002","volume":"43","year":"2006","journal-title":"Hepatology"},{"key":"lt24744-bib-0023-20240115","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1038\/ajg.2016.327","article-title":"A randomized, multi\u2010center, open\u2010label study to evaluate the efficacy of carvedilol vs. propranolol to reduce portal pressure in patients with liver cirrhosis","volume":"111","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"lt24744-bib-0024-20240115","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","article-title":"Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension","volume":"63","year":"2015","journal-title":"J Hepatol"},{"key":"lt24744-bib-0025-20240115","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0168-8278(98)80288-2","article-title":"Hemodynamic changes in patients developing effective hypovolemia after total paracentesis","volume":"28","year":"1998","journal-title":"J Hepatol"},{"key":"lt24744-bib-0026-20240115","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1136\/gut.50.1.90","article-title":"Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: a randomised pilot study","volume":"50","year":"2002","journal-title":"Gut"},{"key":"lt24744-bib-0027-20240115","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.jhep.2011.01.034","article-title":"Beta\u2010blockers cause paracentesis\u2010induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross\u2010over study","volume":"55","year":"2011","journal-title":"J Hepatol"},{"key":"lt24744-bib-0028-20240115","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1002\/hep.28575","article-title":"Propranolol use beyond 6 months increases mortality in patients with Child\u2010Pugh C cirrhosis and ascites","volume":"64","year":"2016","journal-title":"Hepatology"},{"key":"lt24744-bib-0029-20240115","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1053\/j.gastro.2014.03.005","article-title":"Nonselective \u03b2 blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis","volume":"146","year":"2014","journal-title":"Gastroenterology"},{"key":"lt24744-bib-0030-20240115","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/apt.12382","article-title":"Non\u2010selective beta\u2010blockers are not associated with serious infections in veterans with cirrhosis","volume":"38","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"lt24744-bib-0031-20240115","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0140-6736(90)91668-Z","article-title":"Meta\u2010analysis of value of propranolol in prevention of variceal haemorrhage","volume":"336","year":"1990","journal-title":"Lancet"},{"key":"lt24744-bib-0032-20240115","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1046\/j.1365-2036.2000.00778.x","article-title":"Review article: primary prophylaxis for portal hypertensive bleeding in cirrhosis","volume":"14","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"lt24744-bib-0033-20240115","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1136\/gutjnl-2013-306502","article-title":"Non\u2010selective \u03b2\u2010blockers are associated with improved survival in patients with ascites listed for liver transplantation","volume":"64","year":"2015","journal-title":"Gut"}],"container-title":["Liver Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Flt.24744","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01445473-201706000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T01:39:35Z","timestamp":1705282775000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01445473-201706000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,26]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1002\/lt.24744","relation":{},"ISSN":["1527-6465","1527-6473"],"issn-type":[{"value":"1527-6465","type":"print"},{"value":"1527-6473","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,26]]}}}